Skip to content

PHARMAPRODUCTS

Active Public limited companyfounded 1983active for 43 yearsPastoor Paquaylaan 81, 3550 Heusden-ZolderKBO/BCE: BE 0424.935.422 subsidiary of #8 oldest company in Heusden-Zolder, Wholesale and retail trade sector

Lifetime

20 annual accounts with figures on one time axis, 42 filings since 1984
peak of €234,115 in 2022
€178,003▼ 17.7%
peak of €193,126 in 2022
€69,239▼ 47.5%
peak of €193,827 in 2025
€193,827▲ 55.6%
€307,204▲ 56.3%
peak of 1.8 FTE in 2024
1.5 FTE▼ 16.7%
Board6 names since 2000
2 directors and 1 other
Owners2 names in the annual accounts
99.87%
Documentsfilings and deeds
18-06-202643 days before the deadline
2025abbreviated format
Gross margin from €216,304 to €178,003Result from €131,777 to €69,239Staff from 1.8 FTE to 1.5 FTENew director 12-02Equity from €124,587 to €193,827Debts from €196,591 to €307,204

Key points

from the 2025 annual accounts

Equity

€193,827 ▲ 55.6%

PHARMAPRODUCTS has made a profit in every financial year since 2006.

Result

€69,239 ▼ 47.5%
€132,0002024€69,2002025

The result fell in 2025 from €131,777 to €69,239.

Turnover

≈ €840,000 estimated

The abbreviated format states no turnover.

Debts

€307,204 ▲ 56.3%
Suppliers
+100,581
Taxes and wages
+16,281
The rest
-6,250

Debts rose by €110,613 in 2025.

Liquidity

2.29 was 1.27 in 2024

Short-term debts fell from €196,591 to €186,354.

Filings

42 annual accounts since 1984
AprilJune31 JulyOctober199520102025

Three of the last ten came late. The 2021 accounts came in latest, 38 days after the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 31,389 companies had the same profile as PHARMAPRODUCTS has now. Each dot stands for 79 companies, two years later.

93.4%
were still trading
6.0%
stopped another way
0.5%
went bankrupt
  • Micro
  • 20 years or older
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more

Another 0.1% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,912 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 31,389 companies, not a prediction for PHARMAPRODUCTS. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Managing director,
Managing director,
  • 100%equity €186,635 (2025) · annual accounts 2025 of
  • 99.87%equity €2.2m (2026) · annual accounts 2025 of
  • consolidatesscore equity €1.5m (2025) · annual accounts 2016
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0424935422
New director appointed, resigned · and act as permanent representatives · Director discharge: · General meeting of 31-12-2024 · Gazette deed
1 director resigning, 1 reappointment resigns as director · reappointed as director and managing director · acts as permanent representative · General meeting of 30-09-2021 · Gazette deed
1 director appointed, 1 resignation, 1 reappointment resigns · appointed · reappointed as managing director · General meeting of 01-06-2017 · Gazette deed
All 53 events

Comparable companies

same main activity, similar in size and age
Company
PHARMAPRODUCTS Heusden-Zolder €501,031 €178,003 38.7% 1.5
APOTEEK VERCAMMEN Aalst €522,422 €171,509 29.8% 1.7
Pharmacie KOHL-ZONDERMAN Ans €453,634 €172,342 75.6% 1.4
Apotheek Jonkers Ilse Balen €525,702 €179,957 30.3% 1.7
Apotheek VEDASTUS Jabbeke €473,393 €178,609 54.7% 1.3
Apotheek Ernens Sint-Truiden €509,057 €217,175 31.4% 1.2
Apotheek Mares De Haan €563,450 €194,736 77.6% 1.6

These companies have the same main activity as PHARMAPRODUCTS: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €454,000 and €563,000, founded between 1979 and 1987.

Official details

Source: KBO
Status
Active since 17-11-1983Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Joint committee
313Pharmacies and pricing offices · annual accounts 2024
Establishment unit
2.023.508.2883550 Heusden-Zolder, since 01-01-1984
Financial year end
31 December
Peppol
Reachable since 10-03-2025
Company details

Annual accounts 2025

€501,031▲ 56.0%
Employeeson 31-12-2025
2=
Filing
Filed on 18-06-2026, 43 days before the end of the filing period
Financials

Insights on PHARMAPRODUCTS

PHARMAPRODUCTS files the abbreviated format. That format states no turnover. The gross margin rose from €127,708 in 2006 to €178,003 in 2025.

holds all the shares. In February 2025, the Official Gazette published the appointment of as managing director.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about PHARMAPRODUCTS

What is the company number of PHARMAPRODUCTS?
The company number of PHARMAPRODUCTS is 0424.935.422. The VAT number is the same number with BE in front: BE 0424.935.422.
Where is PHARMAPRODUCTS based?
The registered office is at Pastoor Paquaylaan 81, 3550 Heusden-Zolder.Company details
What does PHARMAPRODUCTS do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of PHARMAPRODUCTS?
PHARMAPRODUCTS is a public limited company (NV).
When was PHARMAPRODUCTS founded?
PHARMAPRODUCTS was founded on 17-11-1983.
Is PHARMAPRODUCTS still active?
Yes, PHARMAPRODUCTS is an active enterprise in the KBO register.
How many employees does PHARMAPRODUCTS have?
PHARMAPRODUCTS had an average of 1.5 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does PHARMAPRODUCTS fall under?
In its 2024 annual accounts, PHARMAPRODUCTS states joint committee 313 (Pharmacies and pricing offices).
What is the turnover of PHARMAPRODUCTS?
The turnover in financial year 2025 is ≈ €840,000. This figure is estimated from the gross margin of €178,003 and 43 comparable companies (NACE 477). It probably lies between €550,000 and €1.8m.
Is PHARMAPRODUCTS profitable?
In financial year 2025, PHARMAPRODUCTS made a profit of €69,239.
Where can I find the annual accounts of PHARMAPRODUCTS?
PHARMAPRODUCTS filed 42 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of PHARMAPRODUCTS due?
PHARMAPRODUCTS must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.